ALNY
Alnylam Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$38.92B
P/E Ratio
73.05
EPS
$3.99
Beta
0.30
52W High
$495.55
52W Low
$280.60
50-Day MA
$314.21
200-Day MA
$391.71
Dividend Yield
—
Profit Margin
12.60%
Forward P/E
31.65
PEG Ratio
0.50
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $4.29B |
| Gross Profit (TTM) | $3.46B |
| EBITDA | $806.94M |
| Operating Margin | 23.00% |
| Return on Equity | 90.40% |
| Return on Assets | 10.10% |
| Revenue/Share (TTM) | $32.52 |
| Book Value | $8.06 |
| Price-to-Book | 36.63 |
| Price-to-Sales (TTM) | 8.87 |
| EV/Revenue | 8.78 |
| EV/EBITDA | 43.50 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 96.40% |
| Shares Outstanding | $133.51M |
| Float | $132.96M |
| % Insiders | 0.17% |
| % Institutions | 100.22% |
Historical Volatility
HV 10-Day
38.19%
HV 20-Day
33.88%
HV 30-Day
36.18%
HV 60-Day
34.48%
HV Rank
43.3%
Volatility is currently expanding
Analyst Ratings
Consensus ($449.48 target)
6
Strong Buy14
Buy8
HoldMore HEALTHCARE Stocks
Data last updated: 5/14/2026